Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naadira Vanker

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 7, 2014
The use of the full blood count and differential parameters to assess immune activation levels in asymptomatic, untreated HIV infectionNaadira Vanker, Hayley Ipp
Acta Haematologica|December 4, 2013
Large unstained cells: a potentially valuable parameter in the assessment of immune activation levels in HIV infectionNaadira Vanker, Hayley Ipp
African Journal of Laboratory Medicine|September 8, 2017
Laboratory test result interpretation for primary care doctors in South AfricaNaadira Vanker, Norman H B Faull
Journal of Clinical Pathology|March 20, 2010
A Six Sigma approach to the rate and clinical effect of registration errors in a laboratoryNaadira Vanker, Johan van Wyk, Annalise E Zemlin, et al.
American Journal of Respiratory and Critical Care Medicine|October 20, 2020
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal ActivitySolomon P le Roux, Caryn Upton, Naadira Vanker, et al.
Respiration; International Review of Thoracic Diseases|November 23, 2021
Mycobacteriophages to Treat Tuberculosis: Dream or Delusion?Andreas H Diacon, Carlos A Guerrero-Bustamante, Bernd Rosenkranz, et al.
Journal of Clinical Immunology|November 20, 2012
Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infectionHayley Ipp, Annalise E Zemlin, Richard H Glashoff, et al.
American Journal of Respiratory and Critical Care Medicine|January 11, 2020
Optimizing β-Lactams against TuberculosisVeronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 7, 2014
The use of the full blood count and differential parameters to assess immune activation levels in asymptomatic, untreated HIV infectionNaadira Vanker, Hayley Ipp
Acta Haematologica|December 4, 2013
Large unstained cells: a potentially valuable parameter in the assessment of immune activation levels in HIV infectionNaadira Vanker, Hayley Ipp
African Journal of Laboratory Medicine|September 8, 2017
Laboratory test result interpretation for primary care doctors in South AfricaNaadira Vanker, Norman H B Faull
Journal of Clinical Pathology|March 20, 2010
A Six Sigma approach to the rate and clinical effect of registration errors in a laboratoryNaadira Vanker, Johan van Wyk, Annalise E Zemlin, et al.
American Journal of Respiratory and Critical Care Medicine|October 20, 2020
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal ActivitySolomon P le Roux, Caryn Upton, Naadira Vanker, et al.
Respiration; International Review of Thoracic Diseases|November 23, 2021
Mycobacteriophages to Treat Tuberculosis: Dream or Delusion?Andreas H Diacon, Carlos A Guerrero-Bustamante, Bernd Rosenkranz, et al.
Journal of Clinical Immunology|November 20, 2012
Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infectionHayley Ipp, Annalise E Zemlin, Richard H Glashoff, et al.
American Journal of Respiratory and Critical Care Medicine|January 11, 2020
Optimizing β-Lactams against TuberculosisVeronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Pageof 2